Related Experiment Video
Updated: May 29, 2026

08:36
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
Published on: July 28, 2022
Staging dementia using proxy-reported activities of daily living
Christina Jonas1, Claudia Schiffczyk, Constanze Lahmeyer
1Department of Psychiatry and Psychotherapy II, Mental Health and Old Age Psychiatry, Ulm University, Germany.
Dementia and Geriatric Cognitive Disorders
|September 29, 2011
Summary
Proxy ratings of activities of daily living (ADL) in dementia patients are influenced by informant characteristics, especially gender. Caution is advised when using ADL scales to evaluate dementia
Area of Science:
- Gerontology
- Neuroscience
- Clinical Psychology
Background:
- Cognitive and behavioral scales may not fully capture dementia's impact on daily life.
- Activities of Daily Living (ADL) scales are often used as complementary assessment tools.
- Understanding factors influencing ADL appraisal is crucial for accurate patient evaluation.
Purpose of the Study:
- To analyze variables that influence the appraisal of Activities of Daily Living (ADL) in dementia patients.
- To investigate the role of informant characteristics in ADL assessments.
- To determine if dementia severity or other patient variables differ between identified clusters.
Main Methods:
- Prospective cohort study design.
- Inclusion of 202 patients diagnosed with dementia and their proxies.
- Analysis of patient and informant-reported variables.
Main Results:
- Two distinct patient clusters were identified based on informant reports.
- Significant differences were observed in variables constituting these clusters.
- Patient dementia severity and other variables were comparable across the two clusters, suggesting informant bias.
Conclusions:
- Proxy ADL ratings are significantly modulated by informant characteristics, particularly gender.
- The findings highlight potential biases in ADL assessments by proxies.
- Cautious interpretation and application of ADL scales are recommended when assessing dementia impact or treatment efficacy.
Related Concept Videos
Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
